Physician profile
Edwin C Amos
NPI 1992720379
$13,827.34
in general payments reported to CMS, 2019-2025
52 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,833 · 2020: $2,465 · 2021: $2,845 · 2022: $1,980 · 2023: $1,898 · 2024: $1,635 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,705 · Education: $0.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,704.97 |
| Education | $0.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,865.74 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $849.43 | 2020-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $753.35 | 2019-2025 | Mavenclad |
| Lundbeck LLC | $643.74 | 2021-2025 | Vyepti |
| Abbvie INC. | $641.70 | 2021-2025 | Ubrelvy, Qulipta |
| Amneal Pharmaceuticals LLC | $641.65 | 2019-2025 | Rytary, Crexont |
| Amgen INC. | $599.94 | 2019-2021 | |
| Biogen, INC. | $586.81 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Janssen Pharmaceuticals, INC | $535.25 | 2020-2022 | |
| Lilly USA, LLC | $480.30 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Ucb, INC. | $464.85 | 2019-2024 | Briviact, Nayzilam |
| Upsher-Smith Laboratories LLC | $458.37 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $372.00 | 2019-2025 | Austedo Xr |
| Pfizer INC. | $337.82 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $293.94 | 2020-2024 | Acthar |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Amos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.